We are live on
!
Find out more
HAM
HHR Asset Management Portfolio holdings
AUM
$552M
1-Year Est. Return
15.61%
This Fund
S&P 500
This Quarter
Est. Return
+17.48%
1 Year Est. Return
-15.61%
3 Year Est. Return
+76.29%
5 Year Est. Return
+157.16%
10 Year Est. Return
–
AUM
$1.01B
AUM Growth
-$17.7M
(-1.7%)
Cap. Flow
-$167M
Cap. Flow
% of AUM
-16.62%
Top 10 Holdings %
Top 10 Hldgs %
47.12%
Holding
39
New
1
Increased
9
Reduced
26
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HEICO Corp
HEI
|
+$18.3M |
| 2 |
Health Catalyst
HCAT
|
+$14M |
| 3 |
Align Technology
ALGN
|
+$8.48M |
| 4 |
Starbucks
SBUX
|
+$2.8M |
| 5 |
Five Below
FIVE
|
+$2.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$44.4M |
| 2 |
BlackLine
BL
|
+$20.1M |
| 3 |
JD.com
JD
|
+$19.5M |
| 4 |
RH
RH
|
+$18.9M |
| 5 |
Salesforce
CRM
|
+$17.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 39.5% |
| 2 | Communication Services | 20.91% |
| 3 | Technology | 20.86% |
| 4 | Financials | 9.14% |
| 5 | Healthcare | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PFPT
26
DELISTED
Proofpoint, Inc.
PFPT
| $16.4M | 1.63% |
155,577
-9,280
| -6% | -$1.03M |
|
|
27
Health Catalyst
HCAT
$132M
| $15.1M | 1.5% |
+412,423
| New | +$14M |
|
28
CRISPR Therapeutics
CRSP
$5.2B
| $3.98M | 0.4% |
47,630
-3,740
| -7% | -$332K |
|
29
Allogene Therapeutics
ALLO
$690M
| $2.47M | 0.25% |
65,510
-3,730
| -5% | -$141K |
|
30
Editas Medicine
EDIT
$447M
| $1.91M | 0.19% |
68,060
-3,880
| -5% | -$126K |
|
|
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.32M | 0.13% |
139,760
-7,960
| -5% | -$86.1K |
|
32
MeiraGTx Holdings
MGTX
$1.19B
| $1.25M | 0.12% |
94,664
-5,390
| -5% | -$71K |
|
33
Voyager Therapeutics
VYGR
$197M
| $896K | 0.09% |
83,918
-4,780
| -5% | -$56.1K |
|
34
Regenxbio
RGNX
$704M
| $857K | 0.09% |
31,130
-1,770
| -5% | -$57.7K |
|
35
Q32 Bio
QTTB
$472M
| $670K | 0.07% |
3,479
-198
| -5% | -$44.4K |
|
|
BLUE
36
DELISTED
bluebird bio
BLUE
| $604K | 0.06% |
865
-50
| -5% | -$39K |
|
|
37
Alibaba
BABA
$308B
| – | – |
-205,690
| Closed | -$44.4M |
|
|
38
BlackLine
BL
$1.73B
| – | – |
-242,491
| Closed | -$20.1M |
|
|
39
JD.com
JD
$44.4B
| – | – |
-323,772
| Closed | -$19.5M |
|
Similar funds
HT
SM
GH
TM
FC
FC
VR
MCM
HHR Asset Management's Q3 2020 Portfolio in Review
As of Q3 2020, HHR Asset Management held 39 positions worth $1.01B, down 1.7% from $1.02B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HHR Asset Management withdrew a net $167M in Q3 2020, closing 3 positions and reducing 26 holdings. Its most notable exit was Alibaba, an estimated $44.4M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 40% of assets, down from 42% a quarter earlier, followed by Communication Services and Technology.
Against the trend, HHR Asset Management opened a new position in Health Catalyst worth $15.1M.
- HHR Asset Management's largest Q3 2020 buy was Health Catalyst: 412,423 shares worth $15.1M.
- HHR Asset Management added most to HEICO Corp in Q3 2020, an estimated $18.3M increase.
- HHR Asset Management's biggest Q3 2020 reduction was RH, cutting an estimated $18.9M.
- HHR Asset Management fully exited Alibaba in Q3 2020, selling an estimated $44.4M.
- HHR Asset Management's ten largest holdings make up 47% of its $1.01B portfolio in Q3 2020.
- HHR Asset Management opened 1 new position and closed 3 in Q3 2020.
- HHR Asset Management's portfolio value fell 1.7% quarter-over-quarter to $1.01B.
Based on HHR Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.